Bailard’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bailard’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,000	Closed	-$1.82M	–	623
2019 Q1	$1.82M	Sell	16,000 -2,000	-11%	-$147K	0.11%	162
2018 Q4	$705K	Sell	18,000 -14,000	-44%	-$607K	0.05%	249
2018 Q3	$1.75M	Sell	32,000 -5,000	-14%	-$342K	0.1%	172
2018 Q2	$3.06M	Sell	37,000 -38,711	-51%	-$2.99M	0.18%	127
2018 Q1	$5.04M	Buy	75,711 +20,556	+37%	+$1.19M	0.32%	68
2017 Q4	$2.84M	Buy	55,155 +14,555	+36%	+$1.05M	0.18%	132
2017 Q3	$3.62M	Hold	40,600	–	–	0.28%	92
2017 Q2	$2.42M	Hold	40,600	–	–	0.2%	119
2017 Q1	$2.17M	Hold	40,600	–	–	0.18%	123
2016 Q4	$2.03M	Hold	40,600	–	–	0.19%	125
2016 Q3	$2.44M	Hold	40,600	–	–	0.23%	104
2016 Q2	$2.08M	Hold	40,600	–	–	0.25%	101
2016 Q1	$1.2M	Buy	+40,600	New	+$1.28M	0.17%	92
2015 Q3	–	Sell	-59,500	Closed	-$3.59M	–	280
2015 Q2	$3.59M	Buy	59,500 +31,500	+113%	+$2.08M	0.55%	25
2015 Q1	$2.17M	Buy	+28,000	New	+$1.61M	0.3%	55

Other funds holding ONCE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bailard's ONCE Position: Q2 2019 in Review

Bailard sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 16,000 shares — an estimated $1.82M sold.

Bailard first reported a position in ONCE in Q1 2015 and held it in 15 quarters. The position peaked at $5.04M in Q1 2018. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

Bailard reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Bailard sold 16,000 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.82M.
Bailard first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 15 quarters.
Bailard's Spark Therapeutics, Inc. Common Stock position peaked at $5.04M in Q1 2018.
194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Bailard's 13F filing for Q2 2019, filed 26 Jul 2019.